Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways

Cell Cycle

Volumn 8, Issue 2, 2009, Pages 268-277

  Lyles, Besstina E ^a   Akinyeke, Tunde O ^a   Moss, Patrice E ^a   Stewart, Lamonica V ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Ciglitazone; Cyclin D1; p21; PPAR; Prostate cancer; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; CELL CYCLE PROTEIN; CIGLITAZONE; CYCLIN D1; P21 ACTIVATED KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOBLASTOMA PROTEIN; ROSIGLITAZONE; SERIN 780; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; WESTERN BLOTTING;

EID: 58549099485     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.2.7584     Document Type: Article

References (51)

1. Society AC. Cancer Facts and Figures 2008. 2008.
2. Santen RJ. Clinical review 37: Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992; 75:685-9.
3. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem 2001; 276:37731-4.
4. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002; 43:177-86.
5. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev of Med 2002; 53:409-35.
6. Xu Y, Iyengar S, Roberts RL, Shappell SB, Peehl DM. Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol 2003; 196:131-43.
7. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000; 97:10990-5.
8. Butler R, Mitchell SH, Tindall DJ, Young CY. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ 2000; 11:49-61.
9. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61:497-503.
10. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6:53.
11. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002; 110:923-32.
12. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58:3344-52.
13. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Downregulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000; 60:5494-8.
14. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101:1569-74.
15. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61:6213-8.
16. Takenokuchi M, Saigo K, Nakamachi Y, Kawano S, Hashimoto M, Fujioka T, et al. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). Acta Haematol 2006; 116:30-40.
17. Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, et al. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005; 67:1342-8.
18. Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 2002; 51:108-16.
19. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, et al. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 2004; 13:1710-6.
20. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 2003; 63:958-64.
21. 1 cell cycle regulators. Biochem Biophys Res Commun 2001; 286:916-22.
22. Ceni E, Mello T, Tarocchi M, Crabb DW, Caldini A, Invernizzi P, et al. Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. World J Gastroenterol 2005; 11:1122-30.
23. Gotoh A, Shirakawa T, Wada Y, Fujisawa M, Okada H, Kamidono S, et al. The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells. BJU Int 2003; 92:314-8.
24. L/Bcl-2 functions independently of PPARgamma. Cancer Res 2005; 65:1561-9.
25. Yang CC, Ku CY, Wei S, Shiau CW, Chen CS, Pinzone JJ, et al. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol 2006; 69:1564-70.
26. Matthews L, Berry A, Tersigni M, D'Acquisto F, Ianaro A, Ray D. Thiazolidinediones are partial agonists for the Glucocorticoid Receptor. Endocrinology 2008.
27. Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, et al. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Arthritis Rheum 2005; 52:759-69.
28. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFNgamma target genes in macrophages. Proc Natl Acad Sci USA 2003; 100:6712-7.
29. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 1995; 26:260-9.
30. Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005; 349:248-60.
31. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26:7561-74.
32. Radhakrishnan SK, Gartel AL. The PPARgamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 2005; 4:582-4.
33. Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, Lu PJ, et al. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J Biol Chem 2008; 283:26759-70.
34. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005; 65:4902-8.
35. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, et al. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006; 25:2736-47.
36. Bonofiglio D, Aquila S, Catalano S, Gabriele S, Belmonte M, Middea E, et al. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol 2006; 20:3083-92.
37. Mody M, Dharker N, Bloomston M, Wang PS, Chou FS, Glickman TS, et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer 2007; 14:305-15.
38. Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 1999; 59:2297-301.
39. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001; 15:797-811.
40. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003; 23:6159-73.
41. WAF1/CIP1. Oncogene 2006; 25:2304-17.
42. Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 2004; 108:41-6.
43. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL, et al. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 2005; 26:753-61.
44. kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal 2005; 17:809-16.
45. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, et al. Involvement of p21(WAF1/Cip1), p27(Kip1) and p18(INK4c) in troglitazone-induced cell cycle arrest in human hepatoma cell lines. Hepatology 2001; 33:1087-97.
46. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 2004; 143:933-7.
47. Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, et al. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. Int J Cancer 2007; 120:702-13.
48. Fehlberg S, Trautwein S, Goke A, Goke R. Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners. Biochem J 2002; 362:573-8.
49. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005; 65:2251-9.
50. Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T, et al. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 2005; 11:4012-21.
51. Jiang M, Shappell SB, Hayward SW. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling in prostate cancer. J Cell Biochem 2004; 91:513-27.